Gain Therapeutics, Inc. (GANX) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $20.84M | +100.6% |
| 2024 | $10.39M | -11.9% |
| 2023 | $11.79M | +61.3% |
| 2022 | $7.31M | -80.2% |
| 2021 | $36.88M | +392.2% |
| 2020 | $7.49M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $20.84M | +100.6% |
| 2024 | $10.39M | -11.9% |
| 2023 | $11.79M | +61.3% |
| 2022 | $7.31M | -80.2% |
| 2021 | $36.88M | +392.2% |
| 2020 | $7.49M | — |